United States Biologic Therapeutics Drugs Market | CAGR 10% | Key Players: Pfizer, Novartis, AstraZeneca, Merck, GSK | North America Leads with 35% Share

Market Overview

The Global Biologic Therapeutics Drugs Market is projected to grow at a CAGR of 10% during the forecast period 2024-2031. Biologic therapeutics are advanced, genetically engineered proteins derived from human genetic material, designed to treat a wide range of medical conditions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/biologic-therapeutics-drugs-market?Juli

These biologics may consist of proteins, sugars, nucleic acids, or complex combinations thereof, and can also include living entities such as cells and tissues. They are developed using natural sources, including humans, animals, and microorganisms, which are further processed into therapeutic products such as vaccines, blood components, monoclonal antibodies, and recombinant therapeutic proteins. The increasing prevalence of chronic diseases, advancements in biotechnology, and rising adoption of personalized medicine are key factors driving the market growth. Additionally, the ability of biologics to target specific disease mechanisms with higher precision compared to traditional small-molecule drugs is enhancing their demand globally.

Recent Developments:

✅ January 2026 - United States: Takeda Pharmaceutical Company Limited initiated Phase II clinical trials for a novel monoclonal antibody targeting autoimmune disorders, aimed at improving efficacy and reducing side effects compared to conventional therapies.

✅ November 2025 - United Kingdom: GlaxoSmithKline (GSK) launched a new recombinant protein therapy for inflammatory bowel disease, enhancing targeted immune modulation and patient outcomes.

✅ September 2025 - Germany: BioNTech SE unveiled an advanced mRNA-based therapeutic platform for oncology, designed to elicit tumor-specific immune responses and improve cancer treatment precision.

✅ August 2025 - India: Sun Pharmaceutical Industries Ltd. introduced a biosimilar therapy for rheumatoid arthritis, providing a cost-effective alternative to branded biologics in emerging markets.

✅ June 2025 - Canada: Viome Life Sciences launched a personalized biologic therapeutic program integrating microbiome profiling with protein-based immunotherapies for chronic inflammatory conditions.

✅ April 2025 - Japan: Otsuka Holdings Co., Ltd. announced development of a peptide-based biologic aimed at neurodegenerative disorders, designed to cross the blood-brain barrier efficiently.

✅ February 2025 - Australia: CSL Limited expanded its portfolio with a recombinant enzyme therapy targeting rare genetic disorders, improving treatment accessibility and patient compliance.

Mergers & Acquisitions:

✅ January 2026 - United States: AbbVie Inc. acquired a biotechnology startup specializing in gene-engineered protein therapeutics to strengthen its biologics pipeline for autoimmune and inflammatory diseases.

✅ October 2025 - Europe: Nestlé Health Science completed the acquisition of a European biopharmaceutical firm focused on biologic drugs for metabolic and gastrointestinal disorders.

✅ August 2025 - India: Dr. Reddy's Laboratories acquired a biologics-focused biotech company developing biosimilar monoclonal antibodies, enhancing its specialty therapeutics portfolio.

✅ July 2025 - Switzerland: Roche Holding AG partnered with a cell-therapy startup to co-develop advanced biologic treatments for oncology and immunology indications.

✅ May 2025 - United States: Amgen Inc. entered a strategic collaboration with a protein-engineering company to co-develop novel recombinant biologics targeting chronic inflammatory and rare diseases.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=biologic-therapeutics-drugs-market?Juli

Key Players:
Pfizer Inc. | Novartis Global | Smith Medical | Concord Biotech | H. Lundbeck A/S | AstraZeneca | Merck & Co. Inc | GlaxoSmithKline plc | Aurobindo Pharma Ltd | Retractable Technologies Inc.

Key Highlights:

Pfizer Inc. - Holds 14% share, driven by its extensive biologics portfolio across oncology, immunology, and rare diseases.

Novartis Global - Holds 12% share, supported by innovative protein therapeutics and gene-engineered biologics.

Smith Medical - Holds 8% share, focused on delivery systems and biologic administration devices.

Concord Biotech - Holds 7% share, known for biosimilar development and cost-effective biologic alternatives.

H. Lundbeck A/S - Holds 6% share, specializing in biologics for neurological and psychiatric disorders.

AstraZeneca - Holds 11% share, driven by monoclonal antibodies and recombinant protein therapies in oncology and respiratory diseases.

Merck & Co. Inc - Holds 10% share, with a strong presence in immunotherapies and vaccine-based biologics.

GlaxoSmithKline plc - Holds 9% share, focused on therapeutic proteins, vaccines, and enzyme-based biologics.

Aurobindo Pharma Ltd - Holds 5% share, primarily developing biosimilars for emerging markets.

Retractable Technologies Inc. - Holds 3% share, providing devices for safe biologic administration and delivery.

Market Segmentation:

By product, vaccines lead the market with approximately 28% share, driven by rising immunization programs and pandemic preparedness initiatives, followed by proteins at 22%, which include monoclonal antibodies and recombinant proteins for various therapeutic indications. Blood and blood products account for around 15%, while gene therapies are emerging rapidly with a 12% share due to advancements in precision medicine. Human cells and tissues hold 10%, allergenic extracts 8%, and other biologics contribute the remaining 5%.

By application, cancer therapies dominate with 26% share, reflecting the increasing adoption of biologics such as monoclonal antibodies and targeted protein therapies. Rheumatoid arthritis accounts for 18%, anemia for 15%, diabetes for 12%, and other applications, including rare diseases and immune disorders, represent 29% of the market.

By source, human-derived biologics constitute the largest segment at 30%, followed by bacteria at 20%, yeast at 15%, avian cell culture at 12%, insect cell culture at 10%, and transgenic sources at 8%, with other sources accounting for 5%. The diversity of sources highlights ongoing innovation in biologics development, enabling scalable production, reduced immunogenicity, and targeted therapeutic effects.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/biologic-therapeutics-drugs-market?Juli

Regional Insights:

North America holds the largest share of the biologic therapeutics drugs market, accounting for approximately 35% of global revenue in 2024. The region's dominance is driven by the presence of key pharmaceutical and biotechnology companies, advanced healthcare infrastructure, strong R&D capabilities, and early adoption of innovative biologics therapies. The United States, in particular, benefits from robust clinical trial networks, favorable regulatory pathways, and significant investments in biologic drug development.

Europe represents the second-largest market with a 28% share, supported by established healthcare systems, government initiatives to promote biologics, and high patient awareness. Countries such as Germany, the United Kingdom, and France are leading in biologics consumption, particularly in oncology, autoimmune disorders, and rare diseases. The region also benefits from a well-developed pharmaceutical manufacturing ecosystem and supportive reimbursement policies.

Asia-Pacific is emerging as the fastest-growing market, contributing around 22% of the global share. Growth is fueled by increasing healthcare expenditure, rising prevalence of chronic and lifestyle diseases, expanding biologics manufacturing capacity in countries such as China and India, and improving healthcare access. Rapid urbanization, growing middle-class populations, and increasing awareness of advanced therapies are further propelling market adoption.

Market Dynamics:

Driver:
The growing adoption of biologic therapeutics is a key factor driving market expansion. Biologic drugs, derived from natural sources such as plants, animals, humans, or microorganisms, offer higher specificity and fewer side effects compared to traditional chemical-based therapies. These drugs are utilized to produce vaccines, blood components, recombinant therapeutic proteins, and other advanced therapeutic products. The enhanced efficacy and safety profile of biologics, coupled with rising reimbursement support from private insurers and government healthcare schemes, is encouraging greater adoption among healthcare providers and patients.

Rising Prevalence of Chronic Diseases and Geriatric Population
The global biologic therapeutics market is significantly supported by the increasing prevalence of chronic conditions, including cancer, diabetes, autoimmune disorders, and cardiovascular diseases. Simultaneously, a growing geriatric population more susceptible to these chronic illnesses is fueling demand for advanced, targeted therapies. The combination of aging demographics and chronic disease prevalence is expected to sustain steady market growth throughout the forecast period.

Expanding Applications of Biologic Products
The biologics market benefits from the broadening applications of biological products in modern healthcare. Biologic products, which may comprise sugars, proteins, nucleic acids, or living components such as cells and tissues, are being increasingly used for disease prevention, diagnostics, and therapeutic interventions. Emerging areas such as gene therapies, cell-based therapies, and advanced recombinant proteins are expanding the scope of biologic applications, thereby driving market growth.

R&D and Clinical Trials Supporting Innovation
Ongoing research, development, and clinical trials are propelling the biologic therapeutics market forward. Pharmaceutical and biotechnology companies are continuously developing novel biologics with improved efficacy, reduced side effects, and enhanced delivery mechanisms. Investments in innovative technologies, including bioprocessing, bioengineering, and precision medicine, are expected to further accelerate market expansion.

Manufacturing Complexity as a Restraint
Despite robust growth drivers, the biologic therapeutics market faces challenges due to the inherent complexities in manufacturing biologics. Biologic drugs are large, structurally complex molecules requiring stringent conditions for production, storage, and transportation. High production costs, strict regulatory compliance, and technical challenges in scaling up processes may hinder market growth, particularly for emerging players.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

cCompetitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.